Effect of the lipoprotein lipase activator NO-1886 on adriamycin-induced nephrotic syndrome in rats

Citation
K. Nakayama et al., Effect of the lipoprotein lipase activator NO-1886 on adriamycin-induced nephrotic syndrome in rats, METABOLISM, 49(5), 2000, pp. 588-593
Citations number
53
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
METABOLISM-CLINICAL AND EXPERIMENTAL
ISSN journal
0026-0495 → ACNP
Volume
49
Issue
5
Year of publication
2000
Pages
588 - 593
Database
ISI
SICI code
0026-0495(200005)49:5<588:EOTLLA>2.0.ZU;2-X
Abstract
Hyperlipidemia associated with nephrotic syndrome may play a role in the de terioration of renal function. Tsutsumi et al have previously reported that the novel compound NO-1886 increases lipoprotein lipase (LPL) activity, re sulting in a reduction of plasma triglycerides and an elevation of high-den sity lipoprotein (HDL) cholesterol in normal rats. The aim of this study wa s to ascertain whether NO-1886 suppresses the renal injury by treatment of the hyperlipidemia in an Adriamycin (Kyowa Hakko Kogyo, Tokyo, Japan) induc ed nephrosis rat model fed a high-protein diet that induced renal dysfuncti on and tubulointerstitial injury. Administration of Adriamycin caused hyper lipidemia, proteinuria, and edema with ascites in rats in 4 weeks. Furtherm ore, a combination of Adriamycin and a high-protein diet increased plasma c reatinine and blood urea nitrogen (BUN) and decreased plasma albumin. Histo logically, in Adriamycin-treated rats, marked interstitial cellular infiltr ation, tubular lumen dilation, and tubular cast formation in the kidney wer e observed. NO-1886 decreased plasma triglyceride and increased HDL cholest erol in Adriamycin-induced nephrotic rats, NO-1886 treatment reduced plasma creatinine and BUN levels and increased plasma albumin in Adriamycin-treat ed rats; it also ameliorated the ascites and proteinuria. Histologically, N O-1886-treated rats showed a quantitatively significant preservation of tub ulointerstitial lesions. These data suggest that NO-1886 may have a protect ive effect against Adriamycin-induced nephrosis with tubulointerstitial nep hritis in rats by a modification of the plasma lipid disorder. Copyright (C ) 2000 by W.B. Saunders Company.